← Health and Human Services (NIH, ARPA-H, CDC…)
Universal Platform for Living Adaptive Toxin-removal (UNI-PLAT)
In short: The purpose of this topic area is to catalyze the development of a universal, “plug-and-play” synthetic biology platform that enables next-generation microbial chassis capable of performing a broad array of programmable functions.
Excerpt from the official topic description. Read the full solicitation before deciding to apply.
| Agency | Health and Human Services (NIH, ARPA-H, CDC…) · ARPA-H |
|---|---|
| Program | — |
| Phase | BOTH, BOTH |
| Topic number | ARPA-H 03 |
| Solicitation | 7599226SN106 |
| Release date | Jun 11, 2026 |
| Open date | Jun 11, 2026 |
| Close date | Sep 30, 2027 |
| Status on SBIR.gov | Open |
View official solicitation SBIR.gov topic page
Full description (from SBIR.gov)
The purpose of this topic area is to catalyze the development of a universal, “plug-and-play” synthetic biology platform that enables next-generation microbial chassis capable of performing a broad array of programmable functions. While this solicitation primarily uses toxin removal as a proof-of-concept in relation to chronic disease management, the platform is intended to be adaptable to a range of challenges across industries such as environmental remediation, biomanufacturing, agriculture, holistic medicine, and therapeutic discovery. The broader goal is to create a stable, reliable, and easily reprogrammable microbial platform that demonstrates potential for cross-sector impact beyond the initial use case.
Possibly related past awards
- Development of GenomeBuild as a Universal Method to Synthesize Genomes by Proteovista LLC (Phase I, 2023, $376,800)
- Microfluidics Platform for Rapid, High-throughput Screening of Therapeutic Bacteriophages Based on Patient Bacterial Isolates by FELIX BIOTECHNOLOGY INC (Phase I, 2022, $314,411)
- DEVELOPMENT OF DIGITAL SATIORX, A VERY LOW COST REMOTELY CONTROLLABLE DISPOSABLE MICRONEEDLE TRANSDERMAL DRUG DELIVERY DEVICE ABLE TO DELIVER ANY LIQUID FDA APPROVED TRANSDERMAL DRUG by TRITON SYSTEMS, INC. (Phase II, 2023, $3,499,793)
Matched by keyword overlap within the same agency from the SBIR.gov public award dataset. Not an official linkage.
Technology areas: Biotechnology · Biodefense & chemical defense
SBIR Radar Pro · Get an email the morning a new topic matches your keywords, plus a personal deadline calendar and CSV export. See Pro ($19/mo, founding price) → or set up free beta alerts.
Get new SBIR/STTR topics every week
New topics, plus everything closing in the next 14 days. Free, one email a week.